Trial Profile

A multi-center, un-controlled, open-labeled trial of the long-term safety of Lamazym aftercare treatment of subjects with alpha-Mannosidosis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Velmanase alfa (Primary)
Indications Alpha-Mannosidosis
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms rhLAMAN-07
Sponsors Chiesi Farmaceutici; Zymenex A/S

Most Recent Events

06 Sep 2023 According to a Chiesi media release, updated integrated analysis of data from phase I/II, III, and follow-up clinical trials presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2023 being held August 29 - September 1, 2023, in Jerusalem, Israel.
08 Nov 2022 Status changed from recruiting to completed.
20 Jul 2020 Status changed from active, no longer recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com